Press Releases
FLAMEL APPOINTS STEPHEN
WILLARD AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND GENERAL
COUNSEL
Lyon, France, August 9, 2000 Flamel Technologies (Nasdaq: FLML) today announced the appointment of Stephen H. Willard as executive vice president, chief financial officer and general counsel of the company. Mr. Willard has fifteen years experience as both a financial and legal advisor to international companies as a vice president of a major investment bank and attorney in two prestigious international law firms. Most recently, he has served as an officer in two international pharmaceutical companies focused on drug delivery and pharmaceutical research.
“I am delighted to welcome Steve to the Flamel team,” said Gerard Soula, president and chief executive officer of Flamel. “Steve brings excellent financial and legal skills, as well as a deep understanding of Wall Street and the investment community, to our company. As we move to an exciting new stage in our development, Steve will play an important role in our growth and success.”
Prior to joining Flamel, Mr. Willard served as vice president – legal affairs for Biovail Corporation, which acquired Fuisz Technologies in mid-1999, where he was executive vice president and general counsel. Previously, Mr. Willard was vice president in the investment banking division of Credit Suisse First Boston and was an attorney at Gibson, Dunn & Crutcher and Shearman & Sterling. He serves as an outside member of the board of directors of a number of companies, including E*TRADE Bank. He is a graduate of Williams College and Yale Law School.
“I am very excited about joining Flamel at this promising time in the company’s history,” commented Mr. Willard. “The company’s technology and management are, in my opinion, first rate and I look forward to contributing all I can to its growth and success.”
Flamel Technologies S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa® nano-encapsulation technology is designed to deliver therapeutic proteins. Micropump® is a controlled release technology for the oral administration of small molecule drugs. Flamel's expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc. Additionally, Flamel has developed new herbicide delivery systems now being tested by Monsanto and has patented a biomaterial, ColCys(TM).
This document contains a number of matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 1999.
